CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-23 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award | +158 | 21,422 | ||
| 2026-02-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −2,041 | $331.96 | $678K | 21,264 |
| 2026-02-13 | Garg Pushkal EVP Chief R&D | Sale | −2,242 | $310.08 | $695K | 24,848 |
| 2026-02-13 | Greenstreet Yvonne Chief Executive Officer | Sale | −6,958 | $310.08 | $2.2M | 85,662 |
| 2026-02-13 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −1,959 | $310.08 | $607K | 31,769 |
| 2026-02-13 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −1,959 | $310.08 | $607K | 23,305 |
| 2026-02-13 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −2,242 | $310.08 | $695K | 59,802 |
| 2026-02-12 | Garg Pushkal EVP Chief R&D | Grant or award | +4,579 | 27,090 | ||
| 2026-02-12 | Greenstreet Yvonne Chief Executive Officer | Grant or award | +14,209 | 92,620 | ||
| 2026-02-12 | Tanguler Tolga EVP, Chief Commercial Officer | Grant or award | +4,000 | 33,728 | ||
| 2026-02-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award 10b5-1 | +4,000 | 25,264 | ||
| 2026-02-12 | Poulton Jeffrey V. EVP, Chief Financial Officer | Grant or award | +4,579 | 62,044 | ||
| 2026-01-13 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −197 | $367.52 | $72K | 23,357 |
| 2026-01-13 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −562 | $368.76 | $207K | 22,795 |
| 2026-01-13 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −644 | $370.00 | $238K | 22,151 |
| 2026-01-13 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −485 | $371.24 | $180K | 21,666 |
| 2026-01-13 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −280 | $372.93 | $104K | 21,386 |
| 2026-01-13 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −122 | $374.33 | $46K | 21,264 |
| 2026-01-12 | Garg Pushkal EVP Chief R&D | Sale | −39 | $353.95 | $14K | 23,982 |
| 2026-01-12 | Garg Pushkal EVP Chief R&D | Sale | −42 | $355.16 | $15K | 23,940 |
Page 10 of 41 · 816 trades